Comparison of serum and urinary biomarker panels with albumin/creatinine ratio in the prediction of renal function decline in type 1 diabetes
Comparison of serum and urinary biomarker panels with albumin/creatinine ratio in the prediction of renal function decline in type 1 diabetes
复制标题
DOI：
10.1007/s00125-019-05081-8
复制
发表时间：
2020-04-01
期刊：
影响因子：
8.2
通讯作者：
Colhoun, Helen M.
中科院分区：
文献类型：
--
作者：
Colombo, Marco;McGurnaghan, Stuart J.;Colhoun, Helen M.
目的/假设我们研究了血清或尿液中的候选生物标志物是否可以改善1型糖尿病肾脏疾病进展的预测，超过先前的eGFR，并将其性能与尿白蛋白/肌酐比值（ACR）进行比较。方法从苏格兰糖尿病研究网络1型生物资源（SDRNT 1BIO）中，我们分别抽取了50%和25%的起始eGFR低于和高于75 ml min（-1）[1.73 m]（-2）的患者（N = 1629），中位随访时间为5.1年。多重ELISA和单分子阵列技术用于测量9种血清生物标志物和13种尿液生物标志物，这是基于我们和其他人使用大型发现和候选研究的先前工作。与最终eGFR和进展至
Aims/hypothesis We examined whether candidate biomarkers in serum or urine can improve the prediction of renal disease progression in type 1 diabetes beyond prior eGFR, comparing their performance with urinary albumin/creatinine ratio (ACR). Methods From the population-representative Scottish Diabetes Research Network Type 1 Bioresource (SDRNT1BIO) we sampled 50% and 25% of those with starting eGFR below and above 75 ml min(-1) [1.73 m](-2), respectively (N = 1629), and with median 5.1 years of follow-up. Multiplexed ELISAs and single molecule array technology were used to measure nine serum biomarkers and 13 urine biomarkers based on our and others' prior work using large discovery and candidate studies. Associations with final eGFR and with progression to